Log In
Sunday 25th February 2018

NICE rejects breast cancer drug

9th July 2010

The National Institute for Health and Clinical Excellence has not approved the use of Avastin to treat breast cancer.

NICE said the drug, known as bevacizumab, was not suitable for use in patients whose cancer had metasised because of "uncertain evidence". "The clinical trial results for bevacizumab were disappointing in that they were unable to prove definitively that the drug could extend the lives of patients with metastatic breast cancer over and above currently available treatments," said NICE Chief Executive Andrew Dillon.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018